Thomas Cluzeau, MD, PhD, discusses the rationale for evaluating azacitidine in combination with APR-246 in patients with TP53-mutant myelodysplastic syndrome and acute myeloid leukemia.
Thomas Cluzeau, MD, PhD
Thomas Cluzeau, MD, PhD, is a professor in Hematology department, CHU of Nice, Côte d'Azur University.
Articles by Thomas Cluzeau, MD, PhD